Description
Minute-Foam® is a flavored aqueous foaming solution of acidulated phosphate sodium fluoride with an optimized low pH and a fluoride ion
concentration of 1.23% w/w.
Minute-Foam® is a flavored aqueous foaming solution of acidulated phosphate sodium fluoride with an optimized low pH and a fluoride ion
concentration of 1.23% w/w.
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 0273-0341-06 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-70f1-d83d-e063-dadaa90ab31f | Oral B Minute-Foam Soultion |
| 0273-0342-06 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-70f1-d83d-e063-dadaa90ab31f | Oral B Minute-Foam Soultion |
| 0273-0345-06 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-70f1-d83d-e063-dadaa90ab31f | Oral B Minute-Foam Soultion |
| 0273-0346-06 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-70f1-d83d-e063-dadaa90ab31f | Oral B Minute-Foam Soultion |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0273-0341-06 | Oral B Minute-FoamMellow Mint | 165 g in 1 BOTTLE | SOLUTION | 165 | 6 | |
| 0273-0342-06 | Oral B Minute-FoamOrange-A-Tangy | 165 g in 1 BOTTLE | SOLUTION | 165 | 6 | |
| 0273-0345-06 | Oral B Minute-FoamBubble Gum | 165 g in 1 BOTTLE | SOLUTION | 165 | 6 | |
| 0273-0346-06 | Oral B Minute-FoamStrawberry | 165 g in 1 BOTTLE | SOLUTION | 165 | 6 | |
| 0273-0347-06 | Oral B Minute-FoamGrape | 165 g in 1 BOTTLE | SOLUTION | 165 | 6 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 0273-0341 | ORAL B MINUTE-FOAM BUBBLE GUM (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM MELLOW MINT (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM ORANGE-A-TANGY (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM STRAWBERRY (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM GRAPE (SODIUM FLUORIDE) SOLUTION [YOUNG DENTAL MANUFACTURING CO 1, LLC] | 6 | Legacy NDC, 1 package rows | 20230105_836627d4-44fb-4a21-a641-7c18569258bb.zip |
| 0273-0342 | ORAL B MINUTE-FOAM BUBBLE GUM (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM MELLOW MINT (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM ORANGE-A-TANGY (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM STRAWBERRY (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM GRAPE (SODIUM FLUORIDE) SOLUTION [YOUNG DENTAL MANUFACTURING CO 1, LLC] | 6 | Legacy NDC, 1 package rows | 20230105_836627d4-44fb-4a21-a641-7c18569258bb.zip |
| 0273-0345 | ORAL B MINUTE-FOAM BUBBLE GUM (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM MELLOW MINT (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM ORANGE-A-TANGY (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM STRAWBERRY (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM GRAPE (SODIUM FLUORIDE) SOLUTION [YOUNG DENTAL MANUFACTURING CO 1, LLC] | 6 | Legacy NDC, 1 package rows | 20230105_836627d4-44fb-4a21-a641-7c18569258bb.zip |
| 0273-0346 | ORAL B MINUTE-FOAM BUBBLE GUM (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM MELLOW MINT (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM ORANGE-A-TANGY (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM STRAWBERRY (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM GRAPE (SODIUM FLUORIDE) SOLUTION [YOUNG DENTAL MANUFACTURING CO 1, LLC] | 6 | Legacy NDC, 1 package rows | 20230105_836627d4-44fb-4a21-a641-7c18569258bb.zip |
| 0273-0347 | ORAL B MINUTE-FOAM BUBBLE GUM (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM MELLOW MINT (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM ORANGE-A-TANGY (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM STRAWBERRY (SODIUM FLUORIDE) SOLUTION ORAL B MINUTE-FOAM GRAPE (SODIUM FLUORIDE) SOLUTION [YOUNG DENTAL MANUFACTURING CO 1, LLC] | 6 | 1 package rows | 20230105_836627d4-44fb-4a21-a641-7c18569258bb.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| SODIUM FLUORIDE | ACTIVE INGREDIENT | 8ZYQ1474W7 | 1 | |
| FLUORIDE ION | ACTIVE MOIETY | Q80VPU408O | 1 | |
| cocamidopropyl betaine | INACTIVE INGREDIENT | 5OCF3O11KX | 1 | |
| POLOXAMER 407 | INACTIVE INGREDIENT | TUF2IVW3M2 | 1 | |
| SODIUM PHOSPHATE, MONOBASIC | INACTIVE INGREDIENT | 3980JIH2SW | 1 | |
| SUCRALOSE | INACTIVE INGREDIENT | 96K6UQ3ZD4 | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 | |
| xylitol | INACTIVE INGREDIENT | VCQ006KQ1E | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0273-0345 | 0273-0345-06 |
| 0273-0341 | 0273-0341-06 |
| 0273-0342 | 0273-0342-06 |
| 0273-0346 | 0273-0346-06 |
| 0273-0347 | 0273-0347-06 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | CAPSULE, EXTENDED RELEASE / ORAL | 40 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | SUSPENSION / ORAL | 10 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | GRANULE, FOR SUSPENSION / ORAL | 23 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | SUSPENSION / INTRATYMPANIC | 63 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | POWDER, FOR SOLUTION / ORAL | 414 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | SUSPENSION, EXTENDED RELEASE / ORAL | 16 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | SOLUTION / ORAL | 800 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | SYRUP / ORAL | 80 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | LOTION / TOPICAL | 71 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | GUM, CHEWING / BUCCAL | 70 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | SPRAY / SUBLINGUAL | 22 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | TABLET / SUBLINGUAL | 12 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | TABLET, ORALLY DISINTEGRATING / ORAL | 360 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SYSTEM / TOPICAL | 14.2 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | FILM, SOLUBLE / ORAL | 29 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | TABLET / ORAL | 45 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.07 %w/v | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | GEL / OPHTHALMIC | 1 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | SUSPENSION / ORAL | 383 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | SOLUTION / OPHTHALMIC | 0.2 %w/v | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | FILM / ORAL | 1 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 13.2 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | TABLET, EXTENDED RELEASE / ORAL | 2752 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | TABLET, EXTENDED RELEASE / ORAL | 1 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | CAPSULE, DELAYED RELEASE / ORAL | 5 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 72 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SOLUTION / ORAL | 25 mg/5ml | ||
| xylitol | XYLITOL | VCQ006KQ1E | POWDER, FOR SUSPENSION / ORAL | 4223 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | GEL / PERIODONTAL | 155 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | TROCHE / ORAL | 60 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | CREAM / TOPICAL | 13 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | SUSPENSION / ORAL | 1500 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | SPRAY, METERED / NASAL | 2 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | TABLET, EFFERVESCENT / ORAL | 1080 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | GEL / TOPICAL | 28 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | LOZENGE / ORAL | 115 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | GUM, CHEWING / BUCCAL | 11915 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | TABLET, CHEWABLE / ORAL | 28 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | GRANULE / ORAL | 5.4 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | POWDER, FOR SUSPENSION / ORAL | 0.01 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | PASTE / ORAL | 180 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | SUSPENSION, EXTENDED RELEASE / ORAL | 9000 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | TABLET / ORAL | 2 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION / INTRAMUSCULAR | 161 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | TABLET / ORAL | 15.04 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | CAPSULE / ORAL | 468 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | TABLET / ORAL | 495 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | FILM, SOLUBLE / ORAL | 33 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | TABLET, FOR SUSPENSION / ORAL | 65 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SYSTEM / IONTOPHORESIS | 14.2 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | SOLUTION / ORAL | 50 mg/5ml | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION / INTRAVENOUS | 161 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 0.22 mg | ||
| xylitol | XYLITOL | VCQ006KQ1E | SOLUTION / ORAL | 21600 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | POWDER, FOR SUSPENSION / ORAL | 400 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | SPRAY / NASAL | 2 mg | ||
| SUCRALOSE | SUCRALOSE | 96K6UQ3ZD4 | TABLET, ORALLY DISINTEGRATING / ORAL | 60 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| f1621bba-8cfa-26d6-e053-2a95a90ac1db | 836627d4-44fb-4a21-a641-7c18569258bb | 2023-01-03 | Warnings | f1621bba-8cfa-26d6-e053-2a95a90ac1db 836627d4-44fb-4a21-a641-7c18569258bb |
Adverse event summaries are temporarily unavailable. Other product information remains available.